BAP1 and Miyoshi myopathy: Even if the role of BRCA1 in MM remains to be elucidated, as both BAP1 and BRCA1 are involved in the DNA damage response, they can be considered biomarkers for targeted therapies with PARP inhibitors (PARPi).